About CARB-X
CARB-X is a Healthcare company based in Boston (United States) founded in 2016. Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed. Its website carb-x.org draws about 14 thousand monthly visits. CARB-X offers products and services including Funding Program and Portfolio Acceleration Tools. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its competitors include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
CARB-X was founded in 2016 and is based in Boston, United States. Antibiotics targeting drug-resistant bacteria are developed by the organization, alongside vaccines and rapid diagnostics. These initiatives are advanced through clinical trial phases within the biotechnology sector. Operations emphasize solutions for antimicrobial resistance, supporting global health efforts in infectious disease management.
- Headquarters Boston, United States
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website carb-x.org
- Social LinkedIn X
- InvestorsWellcome
& 1 more
Products & Services of CARB-X
CARB-X offers a comprehensive portfolio of products and services, including Funding Program and Portfolio Acceleration Tools.
Provides grants for antibacterial research projects.
Offers resources for advancing drug development initiatives.
Funding Insights of CARB-X
- Total Rounds 1
- Investors Count 2
All 1 funding rounds of CARB-X with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2022 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in CARB-X
CARB-X has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Wellcome and BARDA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health research and advocacy are funded globally by the foundation. | 1936 | wellcome.org | London, United Kingdom | |
BARDA is focused on developing medical countermeasures for public health security. | medicalcountermeasures.gov | United States |
Investor details for CARB-X
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CARB-X
25 people are tracked at CARB-X (13 in leadership, 12 in team).
| Name | Role | Group |
|---|---|---|
Will Hall | Director Of External Affairs | Leadership |
Genevieve Holmes | Chief Operating Officer | Leadership |
Barry Eisenstein | Chief Medical Officer | Leadership |
Tina Mercado-Bradford | Associate Director, Financial Systems & Reporting | Leadership |
Ed Buurman | Alliance Director | Leadership |
Richard Alm | Chief Scientific Officer | Leadership |
Kevin Outterson | Executive Director | Leadership |
Trudy Grossman | Alliance Director | Leadership |
Betsy Wonderly Trainor | Alliance Director | Leadership |
Kathleen Chardavoyne | Director, Project Management Office | Leadership |
Betsy W. | Diagnostics Alliance Director | Leadership |
Erin Duffy | Chief Of Research & Development | Leadership |
Damiano De Felice | Chief Of External Affairs | Leadership |
Colin Mcgoodwin | Accelerator Manager | Team |
Olga Grush | Financial Operations Manager | Team |
Kristen Morris | Finance And Grants Manager | Team |
Brittainy Roth | Finance And Grants Manager | Team |
Sarah Walker | R&d Process Manager | Team |
Allison Evans | Project Manager | Team |
Heather Tobin | Research Compliance Manager | Team |
5 more people are available in the full profile.
Complete people profiles for CARB-X
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CARB-X
2 dated milestones of CARB-X across 6 years, from founding to its latest funding, stage changes and deals.
- Founded CARB-X is founded.
- Funding First funding round.
Competitors of CARB-X
CARB-X has 3 listed competitors in our database, 3 of them funded. They include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| melinta.com | 2000 | Morristown, United States | $186M | 290 | Developer of bacterial ribosome-targeting drugs for MDR infections | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. |
Detailed competitors of CARB-X
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CARB-X
The website of CARB-X (carb-x.org) receives about 14K visits a month and ranks #1,082,667 among all websites worldwide, #1,343 in Biotechnology and Pharmaceuticals.
- Monthly visits14K
▼ 19.1% vs previous month
- Unique visitors7.8K
per month
- Global rank#1,082,667
among all websites
- Category rank#1,343
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit4.2
- Average visit1 min 10 sec
- DevicesDesktop 22% · Mobile 78%
Websites whose visitors overlap most with CARB-X. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
clpmag.com | clpmag.com | 100% | #1,079,446 | – | |
labmedica.com | labmedica.com | 96% | #1,372,971 | – | |
| biomerieux.com | 88% | 253K | #155,524 | View details | |
| cff.org | 80% | 211.4K | #262,012 | View details |
Top companies in Infectious Diseases
3 companies that operate in the same segment as CARB-X (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Carb-X
Complete news archive for CARB-X
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CARB-X
CARB-X was founded in 2016 and raised its 1st funding round 6 years after it was founded.
CARB-X is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
CARB-X was founded in 2016 and is based in Boston, United States. Antibiotics targeting drug-resistant bacteria are developed by the organization, alongside vaccines and rapid diagnostics. These initiatives are advanced through clinical trial phases within the biotechnology sector. Operations emphasize solutions for antimicrobial resistance, supporting global health efforts in infectious disease management.
CARB-X's top competitors include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics.
CARB-X offers Funding Program and Portfolio Acceleration Tools.